口腔鳞癌组织中尿激酶型纤溶酶原激活剂及其抑制剂活性与颈淋巴结转移的关系.docVIP

???? 口腔鳞癌组织中尿激酶型纤溶酶原激活剂及其抑制剂活性与颈淋巴结转移的关系 ???? ????　提　要　采用发色底物法测量了口腔鳞癌组织及相应癌旁组织中尿激酶型纤溶酶原激活剂（uPA）和纤溶酶原激活剂的抑制剂（PAI-1）的活性，并分析其与口腔鳞癌各病理参数的关系。结果显示：肿瘤组织中uPA及PAI-1活性远高于相应癌旁组织（P＜0．01）；肿瘤组织中uPA及PAI-1活性与肿瘤大小、组织学分级无关，但uPA活性与临床分期有关；有转移的肿瘤组织中uPA及PAI-1活性远高于无转移肿瘤组织（P＜0．01）；9例淋巴结转移灶中，有7例uPA及PAI-1活性高于原发癌组织。本文结果提示：uPA及PAI-1活性升高可能是促进口腔鳞癌细胞发生转移的因素之一。　　关键词　口腔鳞癌　　转移　　纤溶酶原激活剂　纤溶酶原激活剂抑制剂 　　　　The Relationship between activity of urokinase-type plasminogen activator and Its inhibitor in oral squamous carcinoma tissue and metastasis to neck lymphnode.　Liu Gang, Li Jingrong. College of Stomatalogy HuBei Medical University, Wuhan, HuBei,430070　　Abstract　Chromogenic substrate assay was used to determine the activity of uPA and PAI-1 in tumor extract, their relationship with clinlcal and pathological parameters were analysed. It was found that activity of uPA and PAI-1 in tumor tissue was much higher than those in the corresponding normal tissue(P＜0.01); There was no relationship between activity of uPA and PAI-1 and size, histalogical classification of tumor, but the activity of uPA had positive relation to clinical stage; The uPA and PAI-1 activity in tumor with metastasis were significantly higher than those in nonmetastasis tumor(P＞0.01),furthermore, it was shown that uPA and PAI-1 in metastastic lymphnode were greatly higher than that in primary tumor. The result indicated elevation of activity of uPA and PAI-1 might be responsible for the metastasis to neck lymphnode.　　Key words　Oral Squamous Carcinoma 　　Metastasis　　Plasminogen ? Activator 　　Plaminogen　　Activator Inhibitor 　　许多研究表明：纤维蛋白溶解系统在恶性肿瘤的浸润和转移过程中可能起着非常重要的作用［1、2］。本文检测了30例口腔鳞癌患者癌组织中尿激酶型纤溶酶原激活剂（uPA）及纤溶酶原激活剂抑制剂I（PAI-1），目的在于阐明它们与口腔鳞癌颈淋巴结转移的关系。 材料和方法 　　1.　临床资料　　30例口腔鳞癌患者均为1997年5月至1998年9月间我院住院病人，术前未接受任何放疗、化疗,其中男性21例，女性9例，年龄29～65岁，平均42岁。临床分期根据UICC口腔癌分期标准。所有原发灶及淋巴结转移灶均经病理检查证实。　　2.　主要仪器及试剂　　uPA和PAI-1活性测定试剂盒由北京医科大学病理系提供，高速低温离心机；酶标测定仪；Morach-2000自动生化分析仪。　　3.　标本采集及处理　　肿瘤组织及癌旁组织离体三十分钟内于液氮中速冻后置-70℃冰箱保存，检测前按文献制备组织抽提液［3］。　　4.　检测方法　　uPA及P